Examkin

All practice questions

4736 questions

All types4,736Multiple choice2,413Multiple select567Numeric127Matching858Ordering771
Question 4081Question →

Match each patient's clinical presentation with the most appropriate post-acute care disposition setting based on standard utilization and functional criteria.

Click a left item, then click its matching right item

Items

Recovering from an ischemic stroke, medically stable, exhibits severe hemiparesis but actively participates in and tolerates 3.5 hours of daily physical and occupational therapy.
Status post complicated abdominal sepsis, hemodynamically stable but requires prolonged mechanical ventilation via tracheostomy and enteral feeding via gastrostomy.
Medically stable following open reduction and internal fixation of a hip fracture, but baseline dementia and postoperative fatigue limit physical therapy participation to 45 minutes per day.
End-stage chronic obstructive pulmonary disease with resting hypoxia, recently opted to forego further intubation or hospitalizations to prioritize symptom relief at home.

Matches

Show answer & explanation

Answer

The stroke patient capable of intensive therapy matches with an Inpatient Rehabilitation Facility (IRF). The ventilator-dependent patient matches with a Long-Term Acute Care Hospital (LTACH). The hip fracture patient with low endurance matches with a Skilled Nursing Facility (SNF). The advanced COPD patient prioritizing comfort matches with Home Hospice Care.
Appropriate disposition relies on matching a patient's medical complexity, rehabilitation stamina, and goals of care with the legal and functional criteria of specific facilities. LTACHs are for prolonged acute needs (vents). IRFs require 3 hours of daily therapy tolerance. SNFs are for skilled needs without the 3-hour tolerance. Hospice is for comfort-focused, end-of-life care.

Step-by-Step Solution

1
Evaluate the patient's medical acuity and ongoing acute care needs.
The ventilator-dependent patient still requires hospital-level care (ventilator weaning), making LTACH appropriate. The others are medically stable for lower-acuity settings or home.
Differentiating between acute (LTACH) and post-acute (IRF, SNF, Home) levels of care is the first branch point in disposition planning.
2
Assess the functional capacity and therapy tolerance of the medically stable rehabilitation candidates.
The stroke patient tolerates 3.5 hours of therapy, qualifying for IRF. The hip fracture patient only tolerates 45 minutes, mandating SNF placement.
Medicare guidelines strictly dictate that IRF admission requires the ability to participate in 3 hours of intense therapy daily; those who cannot must go to a SNF.
3
Identify goals of care and disease trajectory for the remaining patient.
The end-stage COPD patient desires symptom relief over life-prolonging measures.
When curative or disease-modifying therapies are ceased in favor of comfort, and life expectancy is limited, hospice is the correct disposition.

Key Concept

Clinical criteria for post-acute care disposition (LTACH, IRF, SNF, and Hospice)
Question 4082Question →

A multicenter clinical trial investigates the efficacy of a newly developed monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with familial hypercholesterolemia. A total of 4,000 patients are enrolled and randomly assigned in equal numbers to receive either the monoclonal antibody or a placebo injection every two weeks. All participants remain on their maximally tolerated statin therapy. Over a 3-year follow-up period, a nonfatal myocardial infarction occurs in 100 of the 2,000 patients in the treatment group, compared to 150 of the 2,000 patients in the placebo group. Based on these findings, what is the number needed to treat (NNT) to prevent one nonfatal myocardial infarction over the 3-year period?

Show answer & explanation

Answer: 40

Answer

40
The Number Needed to Treat (NNT) is calculated as the inverse of the Absolute Risk Reduction (ARR). By determining the incidence of the outcome in both the placebo group (150/2000=7.5%150/2000 = 7.5\%) and the treatment group (100/2000=5.0%100/2000 = 5.0\%), we find an ARR of 2.5%2.5\% (or 0.0250.025). Dividing 11 by 0.0250.025 yields exactly 4040, meaning 4040 patients must be treated with the PCSK9 inhibitor over a 33-year period to prevent one nonfatal myocardial infarction.

Step-by-Step Solution

1
Calculate the Control Event Rate (CER) in the placebo group.
CER=1502000=0.075CER = \frac{150}{2000} = 0.075 (7.5%7.5\%)
The CER establishes the baseline risk of the outcome without the experimental intervention.
2
Calculate the Experimental Event Rate (EER) in the treatment group.
EER=1002000=0.050EER = \frac{100}{2000} = 0.050 (5.0%5.0\%)
The EER represents the risk of the outcome when the experimental intervention is applied.
3
Calculate the Absolute Risk Reduction (ARR).
ARR=CER−EER=0.075−0.050=0.025ARR = CER - EER = 0.075 - 0.050 = 0.025 (2.5%2.5\%)
The ARR quantifies the absolute decrease in the risk of the outcome attributable to the intervention.
4
Calculate the Number Needed to Treat (NNT).
NNT=1ARR=10.025=40NNT = \frac{1}{ARR} = \frac{1}{0.025} = 40
The NNT indicates how many patients must be treated to prevent one additional adverse outcome.

Key Concept

Number Needed to Treat (NNT)
Question 4083Question →

A biostatistics consulting group at an academic medical center is evaluating the statistical analysis plans of several proposed clinical studies. The consultants must identify the primary statistical consequence of specific trial design choices. Match each methodological decision to its most direct impact on hypothesis testing parameters.

Click a left item, then click its matching right item

Items

Switching from an independent-groups design to a matched-pairs design with the same total number of participants
Conducting multiple sequential interim analyses for efficacy without adjusting the nominal significance level
Reducing the anticipated effect size (minimally clinically important difference) used in the planning phase while keeping sample size fixed
Applying a Bonferroni adjustment for analyzing multiple secondary endpoints

Matches

Show answer & explanation

Answer

1) Matched-pairs design -> Increases power by reducing variance. 2) Multiple interim analyses -> Inflates overall Type I error rate. 3) Reducing effect size -> Increases Type II error and reduces power. 4) Bonferroni adjustment -> Maintains family-wise alpha but increases false-negatives.
Each methodological decision manipulates the delicate balance between α\alpha (false positives), β\beta (false negatives), and variance. Matched pairs isolate the intervention effect by stripping away between-subject noise (variance), boosting power. Interim analyses act as multiple 'rolls of the dice,' which compounds the risk of a false positive if unadjusted. Shrinking the target effect size without adding more participants means the study lacks the statistical 'resolution' to detect the difference, raising Type II errors. Finally, Bonferroni corrections strictly control false positives but create a highly conservative threshold that drives up false negatives.

Step-by-Step Solution

1
Evaluate the effect of a matched-pairs design.
It controls for confounding inter-subject baseline variables.
By controlling for baseline variability, the standard error decreases, which mathematically increases the test statistic and statistical power.
2
Assess the impact of unadjusted multiple interim analyses.
It leads to repeated significance testing.
Repeatedly testing data without an alpha-spending function geometrically increases the probability of finding a false positive (inflating the Type I error rate).
3
Determine the consequence of reducing the expected effect size without altering sample size.
The trial is attempting to detect a smaller difference with the same mathematical leverage.
Detecting a smaller effect size requires a larger sample. Keeping the sample size fixed drops the study's power, increasing the risk of a Type II error (false negative).
4
Analyze the trade-off of a Bonferroni adjustment.
It sets a much stricter threshold (α/n\alpha/n) for statistical significance.
While it successfully prevents the inflation of family-wise Type I errors, the stricter threshold inherently makes it harder to detect true differences, lowering power and raising Type II error risk.

Key Concept

Hypothesis Testing and Statistical Power
Question 4084Question →

An independent senior living facility resident presents to her primary care physician for a scheduled medication review. The patient is 71 years old and has a medical history significant for paroxysmal atrial fibrillation, osteoarthritis, and osteoporosis. Three weeks ago, a cardiologist prescribed dabigatran for stroke prophylaxis. Today, the patient brings all her medication bottles in a bag and states, "I am terrified of this new blood thinner. I read online that it causes fatal bleeding. I have decided to stop taking it and instead use St. John's wort and my usual high-dose ibuprofen." She demonstrates a clear understanding of her medical conditions and the basic purpose of her medications.

Which of the following is the most appropriate initial statement by the physician?

Show answer & explanation

Answer: It is understandable that you are worried about bleeding. Can you tell me more about what you read regarding this medication?

Answer

The most appropriate initial statement is to validate the patient's concerns and ask an open-ended question to explore her specific beliefs about the medication.
The most effective initial step in patient health education and counseling, particularly when a patient expresses fear or non-adherence, is to validate their emotional state and explore their specific illness beliefs. This patient-centered approach builds the therapeutic alliance and helps the physician tailor subsequent medical education to the patient's exact misunderstandings. While the patient is proposing a medically dangerous alternative regimen, correcting her facts immediately without addressing her primary fear will likely increase resistance and fail to resolve the underlying hesitancy.

Step-by-Step Solution

1
Analyze the patient's statement and emotional state.
The patient is expressing severe anxiety ('terrified') about a newly prescribed medication and is planning to switch to a medically unsafe alternative regimen.
Identifying the emotional driver is crucial for selecting the appropriate communication strategy.
2
Determine the best communication framework for medication hesitancy.
The 'explore before explaining' model is the standard of care in clinical counseling.
A physician must understand the specific root of a patient's fear and establish a therapeutic alliance before providing targeted medical facts.
3
Evaluate the response choices against patient-centered communication principles.
The response that validates the patient's emotion and asks an open-ended question is the only one that effectively builds the therapeutic alliance without immediately lecturing or dismissing the patient.
Other choices rely on premature education, authoritarian directives, or inappropriate deflection, which typically increase patient resistance.

Key Concept

Patient-Centered Communication and Medication Adherence Counseling
Question 4085Question →

A 5252-year-old man presents to the clinic for a general health assessment. He was recently hired for a new job and wishes to ensure his immunizations and screenings are up to date, noting he has not seen a healthcare provider since he was 4646 years old. He has no physical complaints and takes no prescription medications. He has smoked 11 pack of cigarettes daily since age 2222. His body mass index is 32 kg/m232 \text{ kg/m}^2, and his blood pressure is 126/78 mmHg126/78 \text{ mmHg}. A review of his past medical records reveals a negative fourth-generation HIV test, a negative hepatitis C antibody test, and a normal screening colonoscopy, all performed 66 years ago. Based on current guidelines, which of the following preventive interventions are indicated for this patient during today's visit? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Low-dose computed tomography of the chest; Recombinant zoster vaccination; Hemoglobin A1c measurement

Answer

The correct interventions are low-dose computed tomography of the chest, recombinant zoster vaccination, and hemoglobin A1c measurement.
Based on current USPSTF and ACIP guidelines, a 52-year-old male with a 30 pack-year smoking history and obesity qualifies for three distinct interventions simultaneously. First, annual low-dose computed tomography is indicated for lung cancer screening (ages 50-80, >=20 pack-years, current smoker). Second, the recombinant zoster vaccine series is recommended for all adults starting at age 50. Third, screening for type 2 diabetes mellitus with a Hemoglobin A1c or fasting glucose is indicated for adults aged 35 to 70 who are overweight or obese.

Step-by-Step Solution

1
Calculate the patient's pack-year smoking history.
He has smoked 1 pack per day for 30 years (from age 22 to 52), yielding a 30 pack-year history.
Accurate pack-year calculation is required to determine eligibility for lung cancer screening.
2
Assess eligibility for lung cancer screening.
Screening is indicated because he is between 50 and 80 years old, has a >20 pack-year history, and is a current smoker.
Annual low-dose computed tomography is standard of care for patients meeting these specific risk criteria.
3
Evaluate age-based adult immunization requirements.
The recombinant zoster vaccine is indicated.
All adults aged 50 and older require the 2-dose recombinant zoster vaccine series, regardless of prior chickenpox or shingles history.
4
Assess metabolic screening criteria based on physical parameters.
Diabetes screening (e.g., Hemoglobin A1c) is indicated.
The patient is in the 35 to 70 age range and has a body mass index indicating obesity, satisfying USPSTF criteria for diabetes screening.
5
Rule out premature or incorrectly sequenced screening modalities.
Prostate-specific antigen testing, abdominal aortic aneurysm screening, and colonoscopy are rejected.
The patient is too young for routine prostate cancer screening (starts at 55) and abdominal aortic aneurysm screening (starts at 65). His colonoscopy interval is 10 years, so he is not due for another 4 years.

Key Concept

Age- and risk-appropriate preventive screening and immunizations for middle-aged adults based on USPSTF and ACIP guidelines.
Question 4086Question →

An 82-year-old woman is evaluated on the medical floor to finalize her discharge plan. She was admitted 6 days ago for an acute right middle cerebral artery ischemic stroke. Her past medical history includes hypertension, hyperlipidemia, and type 2 diabetes mellitus. Her current medications include aspirin, atorvastatin, lisinopril, and metformin. She is medically stable, and her vital signs are within normal limits. Her basic metabolic panel is notable for a serum sodium of 133 mEq/L, which is unchanged from her baseline value from 6 months ago. The remainder of her laboratory results are normal.

Neurologic examination shows a dense left-sided hemiparesis and left-sided spatial neglect. She requires maximum assistance for transfers and most activities of daily living. A physical therapy evaluation notes that the patient is highly motivated and follows commands well. However, she currently tolerates a maximum of 45 to 60 minutes of combined physical and occupational therapy per day due to significant post-stroke fatigue. Prior to this admission, she lived alone in a single-story home and was completely independent. Her son, who is her healthcare proxy, is heavily involved and asks about the next steps in her care.

Which of the following is the most appropriate disposition for this patient?

Show answer & explanation

Answer: Discharge the patient to a skilled nursing facility

Answer

Discharge the patient to a skilled nursing facility
The most appropriate disposition for this medically stable patient is a skilled nursing facility (SNF). Following a stroke, patients with significant functional deficits (e.g., hemiparesis, requiring maximum assistance) benefit greatly from ongoing rehabilitation. The choice between an inpatient rehabilitation facility (IRF) and a SNF depends largely on the patient's endurance and ability to tolerate intensive therapy. Guidelines typically require a patient to be able to actively participate in and tolerate at least 3 hours of intensive therapy per day (physical, occupational, and/or speech therapy combined) to qualify for an IRF. Because this patient fatigues easily and can only tolerate 45 to 60 minutes of therapy per day, she does not meet the criteria for an IRF. An SNF provides 'subacute' rehabilitation tailored to patients with lower endurance, allowing them to participate in 1 to 2 hours of therapy per day while still receiving 24-hour skilled nursing care.

Step-by-Step Solution

1
Evaluate the patient's medical stability for discharge.
The patient is medically stable; the mild hyponatremia is at her baseline and does not require acute inpatient care.
To determine if the patient is ready to safely transition out of the acute hospital setting.
2
Assess the patient's rehabilitation needs, functional capacity, and safety at home.
The patient has significant functional deficits (dense hemiparesis, max assist for transfers) requiring inpatient rehab. She lives alone, making home discharge unsafe. She only tolerates 45-60 minutes of therapy daily.
To determine the appropriate level and intensity of post-acute rehabilitation care.
3
Match the patient's functional capacity to specific disposition criteria.
The patient meets criteria for a skilled nursing facility (SNF) because she requires ongoing skilled rehabilitation but cannot meet the 3-hour daily therapy requirement for an inpatient rehabilitation facility (IRF).
To select the definitive care setting that aligns with Medicare/insurance utilization criteria and maximizes the patient's potential for functional recovery.

Key Concept

Patients who require post-acute rehabilitation but cannot tolerate the intensive requirement of 3 hours of therapy per day at an inpatient rehabilitation facility (IRF) should be discharged to a skilled nursing facility (SNF) for subacute rehabilitation.
Question 4087Question →

A 28-year-old man is diagnosed with his first episode of uncomplicated major depressive disorder. After shared decision-making, he is started on oral escitalopram 10 mg daily. He has no history of psychiatric hospitalizations, suicide attempts, or substance use disorders. Assuming the patient experiences an uncomplicated clinical course with eventual full remission and no severe adverse effects, arrange the following clinical management and monitoring steps in the correct chronological sequence.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct chronological sequence is: early safety and tolerability check, assessment of initial response, confirmation of full remission, completion of a 4-to-9 month continuation phase, followed by a gradual medication taper.
The standard of care for treating an initial episode of major depressive disorder follows a strict timeline: acute phase monitoring for side effects/safety (1-2 weeks), assessing initial response to determine dose adequacy (4-6 weeks), confirming remission (8-12 weeks), sustaining the dose during the continuation phase (4-9 months post-remission) to prevent relapse, and finally tapering the medication safely if no further episodes occur.

Step-by-Step Solution

1
Identify the immediate monitoring priorities upon initiating selective serotonin reuptake inhibitor (SSRI) therapy.
Early evaluation (1-2 weeks) focuses on tolerability, side effects, and emergent suicidality rather than therapeutic efficacy.
SSRIs can cause early activation and gastrointestinal side effects, and patients require close safety monitoring before the therapeutic benefit begins.
2
Determine the expected timeline for initial clinical response.
The initial therapeutic response is assessed at 4-6 weeks to guide dose titration.
Antidepressants have a delayed onset of action. Assessing efficacy too early leads to premature dose changes, while waiting too long prolongs patient suffering.
3
Identify the endpoint of the acute treatment phase.
Full symptomatic remission is expected at 8-12 weeks of optimized therapy.
The goal of acute phase treatment is complete symptom resolution and functional recovery, not just a reduction in symptom severity.
4
Establish the management plan immediately following remission.
The patient must enter the continuation phase, maintaining the same effective dose for 4-9 months.
The risk of relapse is highest in the months immediately following remission; continuation therapy consolidates the recovery.
5
Determine the criteria for treatment discontinuation.
Medication is gradually tapered and discontinued only after the continuation phase is completed for a single, uncomplicated depressive episode.
Lifelong maintenance is not indicated for a first episode without high-risk features, but abrupt discontinuation can cause withdrawal symptoms.

Key Concept

Longitudinal monitoring and treatment phases for major depressive disorder (MDD) include acute treatment (focusing on tolerability, then response, then remission), a continuation phase to prevent relapse, and appropriate discontinuation.
Question 4088Question →

A hospital care team is coordinating the disposition of a 34-year-old man who has been receiving inpatient treatment for methicillin-resistant Staphylococcus aureus (MRSA) tricuspid valve endocarditis. He was admitted 14 days ago after presenting with fever and pleuritic chest pain. His hospital course was initially complicated by septic pulmonary emboli, but he has been afebrile and hemodynamically stable for the past week. His blood cultures have been negative for 10 days, and a repeat echocardiogram shows a decrease in the size of the tricuspid vegetation with no new complications. The patient has a documented history of severe opioid use disorder involving intravenous heroin. He is currently stabilized on buprenorphine-naloxone therapy, which was initiated during this admission. The infectious disease service determines he requires 4 more weeks of antimicrobial therapy. The patient is eager to leave the hospital, stating he has stable housing with his parents and reliable transportation to appointments. Which of the following is the most appropriate disposition and transition of care plan for this patient?

Show answer & explanation

Answer: Transition to a highly bioavailable oral antimicrobial regimen and discharge home with close outpatient follow-up

Answer

Transition to a highly bioavailable oral antimicrobial regimen and discharge home with close outpatient follow-up
The correct answer involves transitioning the patient to an oral antimicrobial regimen and discharging him home. This patient has right-sided MRSA endocarditis and is clinically stable (afebrile, hemodynamically stable, negative blood cultures for 10 days, improving echocardiogram). Historically, infective endocarditis required 6 weeks of continuous intravenous antibiotics. However, recent evidence and updated guidelines support transitioning stable patients to highly bioavailable oral antibiotics (such as linezolid or TMP-SMX plus rifampin) to complete their treatment course. This is particularly critical for patients with a history of intravenous drug use. Discharging this patient home with a peripherally inserted central catheter (PICC) for outpatient parenteral antimicrobial therapy (OPAT) carries a severe risk of line misuse for illicit drug injection and subsequent life-threatening infections. Because he has stable housing, reliable transportation, and is engaged in opioid use disorder treatment, transitioning to oral therapy and discharging him home is the safest and most appropriate evidence-based disposition.

Step-by-Step Solution

1
Evaluate the patient's clinical stability and required ongoing medical therapy.
The patient is hemodynamically stable, afebrile, and has negative blood cultures, but requires 4 more weeks of MRSA coverage for endocarditis.
Determining acute medical stability is the prerequisite for assessing readiness for transition out of the inpatient care setting.
2
Assess the patient's psychosocial status and specific risks related to standard disposition pathways.
The patient has a history of severe opioid use disorder involving intravenous heroin, making outpatient central venous access highly dangerous.
Social determinants and addiction history directly impact the safety of standard discharge modalities like outpatient parenteral antimicrobial therapy (OPAT).
3
Determine the most appropriate, evidence-based care setting and modality for completing therapy.
Transition to an oral antibiotic regimen and discharge home is selected.
Oral step-down therapy is safe and effective for stabilized endocarditis and completely avoids the severe risks of central line abuse associated with OPAT in this vulnerable population.

Key Concept

Appropriate care setting transition for medically stable patients with a history of intravenous drug use requiring prolonged antimicrobial therapy involves prioritizing safe, highly bioavailable oral regimens over risky outpatient intravenous access.
Estimated Time:1m 30s
Question 4089Question →

A 75-year-old man is hospitalized with a severe exacerbation of end-stage chronic obstructive pulmonary disease (COPD). Over the past year, he has had four hospitalizations and two intensive care unit admissions for hypercapnic respiratory failure. Despite maximal medical therapy, including continuous home oxygen, inhaled bronchodilators, and systemic glucocorticoids, he remains markedly dyspneic at rest. During morning rounds, the patient clearly and consistently states, "I cannot keep living like this. I want to go home and focus entirely on my comfort. I do not want to return to the hospital ever again." His son, who is visiting from out of state, becomes visibly upset and tells the physician, "You cannot let him do this. He is just depressed and legally incompetent to make this choice because of his illness. He needs to go to a pulmonary rehabilitation facility." The physician evaluates the patient and finds that he is alert, oriented, and understands his prognosis. He clearly articulates the risks, benefits, and rationale for his decision without any clinical evidence of depression affecting his judgment. Which of the following is the most appropriate next step in management?

Show answer & explanation

Answer: Arrange for discharge home with hospice care services

Answer

Arrange for discharge home with hospice care services.
The most appropriate next step is to arrange for discharge home with hospice care services. This patient has end-stage COPD and has clearly articulated a desire to forgo further hospitalizations in favor of comfort-focused care at home. The core ethical principle in this scenario is respect for patient autonomy. The physician has evaluated the patient and determined that he possesses clinical decision-making capacity: he understands his condition, appreciates the consequences of his choices, and provides a logical rationale for his decision. Although the son asserts the patient is "legally incompetent," legal competence is determined by a judge, whereas clinical capacity is assessed by the treating physician. Because the patient has capacity, his autonomous medical decisions must be honored, regardless of family disagreement.

Step-by-Step Solution

1
Assess the patient's clinical decision-making capacity.
The patient is alert, oriented, understands his prognosis, and can clearly communicate his rationale.
Capacity assessment is required before a patient can autonomously direct their own medical care, including the refusal of life-prolonging treatments.
2
Evaluate the son's claim regarding legal incompetence.
The physician determines the son is confusing clinical capacity with legal competence.
Legal competence is a legal determination made by a judge, whereas clinical capacity is a medical determination made by the treating physician at the bedside.
3
Determine the appropriate disposition based on the capacitated patient's wishes.
The patient is discharged home with hospice services.
A capacitated patient's autonomous decision overrides the conflicting wishes of family members, dictating the plan of care.

Key Concept

Clinical decision-making capacity versus legal competence, and honoring capacitated patient autonomy over family objections.
Question 4090Question →

A retired accountant accompanied by his adult son arrives for a scheduled health maintenance visit. The 67-year-old patient has a documented history of type 2 diabetes mellitus, essential hypertension, and a myocardial infarction that occurred two years prior. His current prescribed regimen includes metformin, metoprolol, and atorvastatin. During the encounter, the son expresses significant frustration, noting that his father frequently skips his daily medications. When the physician inquires about this behavior, the patient crosses his arms and states, 'I feel perfectly fine. I do not see why I need to swallow a handful of chemicals every morning when I am not even sick.' Which of the following is the most appropriate initial communication strategy by the physician?

Show answer & explanation

Answer: What is your understanding of how high blood pressure and diabetes affect your body even when you feel well?

Answer

The correct action is to ask the patient: 'What is your understanding of how high blood pressure and diabetes affect your body even when you feel well?'
The correct response relies on the foundational communication skill of exploring a patient's baseline understanding before delivering medical information (often conceptualized in the Ask-Tell-Ask or Explore-Explain-Explore frameworks). This patient is exhibiting a common barrier to adherence in chronic disease management: the absence of symptoms leads to the belief that the illness is absent. By asking an open-ended question about his understanding of hypertension and diabetes, the physician validates the patient's perspective, builds therapeutic rapport, and pinpoints the exact knowledge gap. Once the patient explains his viewpoint, the physician can tailor subsequent education to explain how these specific 'silent' diseases cause long-term vascular damage even when the patient feels well.

Step-by-Step Solution

1
Identify the primary barrier to medication adherence presented in the vignette.
The patient believes that because he lacks acute symptoms ('I feel perfectly fine'), he does not have a disease that requires treatment ('not even sick').
Recognizing the specific health belief is essential before formulating a counseling response.
2
Determine the most appropriate communication framework for a patient with a conflicting health belief.
Apply the 'explore before explain' (or Ask-Tell-Ask) model of patient education.
Providing education or warnings without first exploring the patient's baseline understanding often leads to resistance and defensiveness.
3
Select the physician response that explores the patient's illness representation.
The option asking the patient about his understanding of his conditions directly addresses his comment while maintaining a non-judgmental stance.
This open-ended question invites the patient to share his mental model of the disease, allowing the physician to later tailor education to that specific knowledge gap.

Key Concept

In patient counseling, physicians must explore a patient's illness beliefs and baseline understanding (health literacy) before providing medical education or attempting to correct non-adherent behaviors.
Estimated Time:1m 15s
Question 4091Question →

A routine health maintenance evaluation is conducted for a 63-year-old female patient with a complex medical history. She is currently managed for seropositive rheumatoid arthritis with weekly methotrexate and subcutaneous etanercept. She also has type 2 diabetes mellitus, maintained on metformin. The patient reports feeling well with no new complaints. She is a lifelong nonsmoker and exercises moderately three times a week.

A review of her preventive care timeline reveals the following:
- Screening colonoscopy at age 54 showed no abnormalities.
- Mammography 8 months ago was reported as normal.
- Bone mineral density testing via DEXA scan at age 59 demonstrated a T-score of -1.1 at the femoral neck.
- She successfully completed the two-dose recombinant zoster vaccination protocol at age 52.
- Her primary care provider administered the 15-valent pneumococcal conjugate vaccine (PCV15) exactly three months ago during a flare of her arthritis.
- Her tetanus-diphtheria-acellular pertussis (Tdap) booster was administered 5 years ago.

Physical examination today demonstrates stable joint findings with no active synovitis. Hemoglobin A1c is 6.8%.

Based on current guidelines, which of the following is the most appropriate next step in this patient's preventive care?

Show answer & explanation

Answer: Administration of the 23-valent pneumococcal polysaccharide vaccine (PPSV23)

Answer

Administration of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) is the most appropriate next step, as she is immunocompromised and has completed the required 8-week waiting period following her PCV15 dose.
The correct intervention is the administration of the 23-valent pneumococcal polysaccharide vaccine (PPSV23). The Advisory Committee on Immunization Practices (ACIP) updated guidelines mandate that adults aged 19 years or older who possess an immunocompromising condition (e.g., iatrogenic immunosuppression via methotrexate and etanercept) and receive PCV15 must subsequently receive PPSV23. Crucially, the minimum interval between these doses is reduced from 1 year (for immunocompetent adults) to 8 weeks for immunocompromised individuals. Because the patient received PCV15 three months ago, she has surpassed the 8-week threshold and is due for PPSV23 to complete her series.

Step-by-Step Solution

1
Analyze the patient's immune status and comorbidities.
The patient has rheumatoid arthritis and is taking methotrexate and etanercept, qualifying her as having an immunocompromising condition.
Immune status directly dictates the choice, sequencing, and minimum intervals of adult vaccinations.
2
Review the patient's pneumococcal vaccination history.
She received PCV15 three months (approximately 12 weeks) ago.
ACIP guidelines require adults initiating vaccination with PCV15 to receive a follow-up dose of PPSV23.
3
Determine the appropriate interval for the follow-up vaccine based on immune status.
For immunocompetent adults, the interval between PCV15 and PPSV23 is at least 1 year. For immunocompromised adults, the interval is shortened to at least 8 weeks.
Immunocompromised patients require expedited broad coverage against pneumococcal serotypes. Since 12 weeks have passed, she is eligible for PPSV23 today.

Key Concept

Adults with immunocompromising conditions who receive the 15-valent pneumococcal conjugate vaccine (PCV15) should receive a follow-up dose of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) at a shortened minimum interval of 8 weeks.
Estimated Time:1m 30s
Question 4092Question →

Paramedics bring a 72-year-old man to the emergency department due to a sudden change in mental status. His daughter reports that over the past 24 hours, he has become increasingly agitated and started conversing with people who are not in the room. He has a 5-year history of Parkinson disease and was recently evaluated for urinary frequency, for which a new oral medication was prescribed 4 days ago. Other medical history includes hypertension and benign prostatic hyperplasia. His home medications include carbidopa-levodopa, lisinopril, and the newly prescribed medication. Vital signs are temperature 37.9∘C37.9^\circ\text{C} (100.2∘F100.2^\circ\text{F}), blood pressure 138/86 mmHg, heart rate 115/min, and respiratory rate 16/min. Physical examination shows flushed, warm, and completely dry skin. His pupils are 7 mm bilaterally and sluggishly reactive to light. Abdominal examination reveals a distended, palpable mass in the suprapubic region and absent bowel sounds. Neurologic examination shows a confused, picking behavior with a resting tremor in the right hand. Which of the following is the most likely diagnosis explaining this patient's acute presentation?

Show answer & explanation

Answer: Anticholinergic toxicity

Answer

The correct answer is anticholinergic toxicity. The patient's presentation of acute delirium, tachycardia, mydriasis, dry skin, absent bowel sounds, and urinary retention shortly after starting a new medication for overactive bladder is highly characteristic of this toxidrome.
This patient's acute presentation of agitation, visual hallucinations, tachycardia, mydriasis, dry/flushed skin, absent bowel sounds, and acute urinary retention (suprapubic mass) represents the classic anticholinergic toxidrome. This is often remembered by the mnemonic 'mad as a hatter, hot as a hare, blind as a bat, red as a beet, dry as a bone, and the bowel and bladder lose their tone.' The patient was recently prescribed a new medication for urinary frequency (overactive bladder). Medications used for this indication, such as oxybutynin or tolterodine, are antimuscarinic agents. Older adults, particularly those with underlying benign prostatic hyperplasia, are highly susceptible to anticholinergic adverse effects, which can rapidly precipitate acute urinary retention and subsequent delirium.

Step-by-Step Solution

1
Analyze the patient's acute symptoms and physical examination findings.
The patient presents with acute delirium, tachycardia, low-grade fever, mydriasis, completely dry skin, absent bowel sounds, and a palpable suprapubic mass indicating urinary retention.
Identifying the constellation of physical signs is necessary to recognize a specific systemic toxidrome.
2
Correlate the physical findings with the patient's recent medical history.
The patient recently started a new medication for urinary frequency. Medications for overactive bladder are typically antimuscarinic agents (e.g., oxybutynin, tolterodine).
Establishing a temporal relationship between a new medication and symptom onset points to an adverse drug event.
3
Synthesize the data to formulate the most likely differential diagnosis.
The combination of antimuscarinic use and the classic peripheral signs (dry skin, dilated pupils, urinary retention, ileus) confirms anticholinergic toxicity, overriding other overlapping causes of delirium.
Distinguishing this toxidrome from other causes of altered mental status in the elderly (such as infection or progression of Parkinson's disease) is critical for appropriate patient management.

Key Concept

Formulating a differential diagnosis for acute altered mental status by identifying classic toxidrome patterns and recognizing anticholinergic toxicity in a geriatric patient with polypharmacy.
Question 4093Question →

A clinical researcher is evaluating the relationship between smoking status and postoperative pulmonary complications following major abdominal surgery. A cohort of 450 adult patients is recruited. Patients are categorized based on their smoking status prior to surgery into three groups: never smokers, former smokers, and current smokers. Following surgery, patients are monitored for 30 days, and their respiratory outcomes are classified into three mutually exclusive categories: no complications, mild complications (requiring supplemental oxygen only), or severe complications (requiring reintubation or intensive care). The investigator plans to perform a statistical analysis to determine if there is a significant association between smoking status and the severity of postoperative pulmonary complications. Assuming all expected cell counts are greater than 5, the researcher sets up a contingency table for a Chi-square test of independence. What is the degrees of freedom for the test statistic in this analysis?

Show answer & explanation

Answer: 4

Answer

4
The appropriate statistical analysis for comparing two categorical variables (smoking status and complication severity) is the Chi-square test of independence. The degrees of freedom for this test are calculated using the formula df=(r−1)×(c−1)df = (r - 1) \times (c - 1), where rr is the number of rows (categories of the first variable) and cc is the number of columns (categories of the second variable). With 3 smoking categories and 3 complication categories, df=(3−1)×(3−1)=2×2=4df = (3 - 1) \times (3 - 1) = 2 \times 2 = 4.

Step-by-Step Solution

1
Identify the appropriate statistical test and its degrees of freedom formula.
The test is a Chi-square test of independence, which uses the formula df=(r−1)×(c−1)df = (r - 1) \times (c - 1).
This formula is standard for evaluating contingency tables to determine how many values can vary freely while maintaining fixed marginal totals.
2
Determine the number of categories for each of the two variables.
Smoking status has 3 categories (r=3r = 3), and pulmonary complications has 3 categories (c=3c = 3).
Mapping the clinical study design to the statistical dimensions is necessary to populate the formula.
3
Calculate the degrees of freedom.
(3−1)×(3−1)=2×2=4(3 - 1) \times (3 - 1) = 2 \times 2 = 4.
Applying the variables to the correct statistical formula yields the final value.

Key Concept

Degrees of freedom for a Chi-square test of independence
Question 4094Question →

A team of researchers is designing a prospective cohort study to investigate the relationship between a novel serum biomarker (measured in ng/mL) and the development of acute respiratory distress syndrome (ARDS) in patients admitted with severe sepsis. They plan to classify the enrolled patients into three independent categories based on their initial sequential organ failure assessment (SOFA) score: mild risk, moderate risk, and high risk. The serum biomarker will be measured once upon admission for all patients. The researchers are meeting to finalize the statistical analysis plan for comparing the continuous biomarker data across these three distinct risk groups. Which of the following statements regarding the appropriate statistical analysis for this study are correct? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: If the biomarker measurements within each risk group follow a normal distribution and have similar variances, a one-way analysis of variance (ANOVA) is the correct test to use.; If the biomarker measurements demonstrate a markedly skewed, non-normal distribution, the Kruskal-Wallis test is the most appropriate statistical method.

Answer

The correct statements are that one-way ANOVA should be used for normally distributed continuous data across three or more independent groups, and the Kruskal-Wallis test should be used if the continuous data are non-normal or skewed.
The correct statements accurately reflect the rules for test selection when comparing a continuous variable across three or more independent groups. One-way ANOVA is the standard parametric approach when data are normally distributed. When data violate the assumption of normality (e.g., skewed distribution), the Kruskal-Wallis test serves as the appropriate non-parametric alternative.

Step-by-Step Solution

1
Identify the independent and dependent variables in the study design.
The independent variable is the risk category (categorical: 3 independent groups). The dependent variable is the serum biomarker level (continuous: ng/mL).
Variable types dictate which statistical tests are mathematically appropriate.
2
Determine the appropriate test for normal parametric data.
Comparing a continuous variable across 3 independent groups requires a one-way ANOVA, assuming normal distribution and equal variances.
ANOVA compares the means of three or more independent groups.
3
Determine the appropriate test for non-normal non-parametric data.
If the continuous data is skewed, the Kruskal-Wallis test must be used.
Kruskal-Wallis is the non-parametric equivalent to one-way ANOVA.
4
Evaluate the distractors based on test assumptions.
Chi-square is for categorical data. Paired t-test is for matched data. A significant ANOVA requires post-hoc testing to find pairwise differences.
Ruling out inappropriate tests based on their foundational assumptions.

Key Concept

Selecting inferential statistical tests based on variable type (continuous vs. categorical), group independence, and data distribution.
Question 4095Question →

A multicenter randomized controlled trial is conducted to evaluate the efficacy of a novel anti-fibrotic agent compared with standard of care for patients with idiopathic pulmonary fibrosis. The primary outcome is disease progression, defined as an absolute decline of ≥\geq 10% in forced vital capacity (FVC) over 5252 weeks. The initial unadjusted analysis reveals a relative risk (RRRR) of 0.680.68 (95%95\% CICI: 0.54−0.850.54-0.85) for disease progression in the novel agent group compared with standard of care.

During the analysis phase, the researchers stratify the trial results based on the presence or absence of the MUC5B promoter genetic variant. The stratified analysis yields the following results:
- MUC5B variant present: RR=0.32RR = 0.32 (95%95\% CICI: 0.21−0.490.21-0.49)
- MUC5B variant absent: RR=1.05RR = 1.05 (95%95\% CICI: 0.81−1.360.81-1.36)

Based on these findings, which of the following is the most appropriate way to interpret and report these data?

Show answer & explanation

Answer: Report the relative risks for each genetic stratum separately because the variant modifies the medication's efficacy.

Answer

Report the relative risks for each genetic stratum separately because the variant modifies the medication's efficacy.
The correct answer accurately identifies that the MUC5B genetic variant is acting as an effect modifier, not a confounder. In epidemiology, a stratified analysis is used to differentiate between confounding and effect modification. If the stratum-specific relative risks are similar to each other but notably different from the crude relative risk, confounding is present. However, if the stratum-specific relative risks are significantly different from one another (as seen here with 0.320.32 vs. 1.051.05), effect modification is present. Because effect modification represents a true biological interaction—meaning the drug is highly effective in patients with the variant but ineffective in those without it—it is not an error to be 'adjusted away.' Instead, the proper statistical approach is to report the stratum-specific results separately to inform clinical decision-making.

Step-by-Step Solution

1
Analyze the relationship between the crude relative risk and the stratum-specific relative risks.
The crude RRRR is 0.680.68. The stratum-specific RRRR s are 0.320.32 and 1.051.05. They are significantly different from each other.
Comparing crude and stratified estimates is the primary method to distinguish between confounding and effect modification.
2
Determine the epidemiological phenomenon present based on the stratified analysis.
Because the RRRR is substantially different depending on the presence or absence of the genetic variant, the variant is an effect modifier.
Effect modification (or interaction) occurs when the magnitude of the effect of an exposure on an outcome differs depending on the level of a third variable.
3
Identify the correct reporting strategy for this phenomenon.
The investigators should report the stratum-specific relative risks separately.
Unlike confounding, which is a nuisance variable that investigators try to control for (e.g., by pooling), effect modification is a real biological phenomenon that provides valuable clinical information and must be reported separately.

Key Concept

Effect modification occurs when the effect of an exposure on an outcome varies depending on the level of a third variable. It is identified when stratified analysis reveals significantly different relative risks between strata, and it should be reported by providing the stratum-specific results separately.
Estimated Time:1m 30s
Question 4096Question →

An informatics board at a tertiary care center is evaluating a newly implemented machine learning algorithm designed to detect acute appendicitis on abdominal ultrasound. To validate the algorithm's performance, a dataset of 150 historical ultrasound scans with known surgical outcomes is assembled. Each of the 150 scans is independently evaluated by both the machine learning algorithm and a senior attending radiologist. The diagnostic result for each scan is recorded categorically as either 'positive' or 'negative' for appendicitis by each evaluator. The board aims to determine if there is a statistically significant difference in the overall proportion of positive diagnoses made by the algorithm compared to the radiologist on these identical scans. Which of the following is the most appropriate statistical test to analyze these data?

Show answer & explanation

Answer: McNemar test

Answer

McNemar test
The correct statistical test is the McNemar test. This study compares a categorical outcome ('positive' or 'negative') between two groups. The groups are paired because the same set of 150 ultrasound scans is being evaluated by two different raters (the machine learning algorithm and the human radiologist). The McNemar test is specifically designed to analyze paired nominal data to determine if there is a statistically significant difference in marginal frequencies (proportions) between two related groups.

Step-by-Step Solution

1
Identify the type of dependent variable being measured.
The outcome variable is categorical (nominal), specifically binary ('positive' or 'negative' for appendicitis).
Determining the variable type (categorical vs. continuous) is the essential first step in selecting a statistical test.
2
Determine if the study groups are independent or paired.
The groups are paired because the exact same 150 ultrasound scans are being evaluated by both diagnostic methods.
Statistical test selection changes depending on whether measurements are drawn from independent samples or are repeated measures on the same subjects/items.
3
Select the appropriate test for paired categorical data.
The McNemar test is chosen.
The McNemar test is specifically designed to compare differences in proportions for paired nominal data.

Key Concept

Selection of statistical tests for paired categorical data
Question 4097Question →

A clinical guidelines committee is evaluating the methodology of four recent observational and experimental studies. To correctly appraise the evidence, the committee must identify the primary methodological flaw or bias affecting each study's validity. Match each study methodology description with the specific epidemiological bias it best illustrates.

Click a left item, then click its matching right item

Items

A screening program detects a novel biomarker for asymptomatic pancreatic cancer 6 months earlier than standard imaging. The 3-year survival rate from diagnosis is higher in the screened cohort, but the age-specific mortality rate remains unchanged.
An observational study compares outcomes of a novel oral anticoagulant versus standard therapy. The novel agent is disproportionately prescribed to patients with severe baseline renal impairment, artificially increasing its apparent bleeding risk.
A 5-year prospective study on cognitive behavioral therapy for insomnia includes only the 45% of participants who completed all therapy sessions in its final analysis, excluding all dropouts from the results.
A retrospective case-control study investigates the link between congenital malformations and maternal herbal tea consumption. Mothers of affected infants are surveyed 5 years post-delivery about their first-trimester dietary habits.

Matches

Show answer & explanation

Answer

Study 1 matches Lead-time bias; Study 2 matches Confounding by indication; Study 3 matches Attrition bias; Study 4 matches Recall bias.
Each study design flaw accurately aligns with a specific epidemiological bias. Early detection increasing apparent survival time without changing overall mortality is the hallmark of lead-time bias. Disproportionate prescription of a treatment to a sicker subgroup, which independently affects the outcome, is confounding by indication. Excluding study dropouts from the final analysis creates attrition bias (a form of selection bias). Finally, surveying patients years after a traumatic event (such as having an infant with anomalies) reliably introduces recall bias compared to a healthy control group.

Step-by-Step Solution

1
Analyze the first study description for survival rate inflation without a true mortality benefit.
Identified as Lead-time bias.
The apparent increase in survival is purely due to earlier detection, not delayed death.
2
Analyze the second study description for baseline differences driving treatment selection.
Identified as Confounding by indication.
The indication for the drug (or provider preference for sicker patients) is independently linked to the adverse outcome (bleeding risk).
3
Analyze the third study description for the effect of excluding study dropouts.
Identified as Attrition bias.
Loss to follow-up and exclusion of non-completers skews the final population, violating intention-to-treat principles.
4
Analyze the fourth study description for potential memory discrepancies between the two groups.
Identified as Recall bias.
Having a child with anomalies prompts stronger, often disproportionate, maternal recollection of potential exposures compared to mothers of healthy children.

Key Concept

Identifying and categorizing epidemiological biases based on study design and participant follow-up flaws.
Estimated Time:1m 30s
Question 4098Question →

A state health informatics registry is utilized to evaluate the real-world effectiveness of a newly approved non-steroidal mineralocorticoid receptor antagonist (MRA) versus standard angiotensin receptor blockers (ARBs) in preventing incident end-stage renal disease (ESRD) among patients with type 2 diabetes. The research group is primarily concerned about confounding by indication; specifically, physicians may preferentially prescribe the novel MRA to patients with significantly higher baseline proteinuria, a factor that independently accelerates progression to ESRD.

To appropriately address baseline proteinuria as a confounding variable, which of the following methodological strategies are valid approaches? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Restricting study inclusion to only those individuals with a baseline urine albumin-to-creatinine ratio strictly between 30 and 300 mg/g.; Incorporating the baseline 24-hour urine protein excretion rate as an independent covariate within a multivariable Cox proportional hazards model.

Answer

The valid approaches to control for confounding in this scenario are restricting the study population to a specific range of proteinuria and adjusting for proteinuria using a multivariable Cox proportional hazards model.
Confounding by indication occurs when a baseline clinical characteristic (proteinuria) influences both treatment selection and the risk of the outcome (ESRD). To determine the independent effect of the MRA, this confounding must be neutralized. Restriction (limiting the study to patients with similar proteinuria levels) is a valid design-phase technique that removes the variation in the confounder. Multivariable Cox proportional hazards regression is a valid analysis-phase technique that mathematically adjusts the risk estimate for the presence of the covariate while correctly handling the time-to-event data.

Step-by-Step Solution

1
Identify the primary methodological threat described in the scenario.
The scenario describes confounding by indication, where baseline proteinuria affects both the likelihood of receiving the new MRA and the risk of the outcome (ESRD).
Recognizing the specific bias dictates which methodological tools are appropriate for mitigation.
2
Evaluate design-phase strategies for controlling confounding.
Restriction limits enrollment to a specific category of the confounder (e.g., only microalbuminuria), effectively eliminating the confounder's variation within the study.
If all subjects have the same level of the confounding variable, it can no longer distort the exposure-outcome relationship.
3
Evaluate analysis-phase strategies for controlling confounding.
Multivariable regression models (such as Cox proportional hazards for survival data) can include the confounder as a covariate, mathematically adjusting the primary risk estimate.
This allows researchers to estimate the independent effect of the medication while holding the confounder constant.
4
Differentiate confounding control from effect modification assessment.
Reporting stratum-specific estimates specifically to show that the effect sizes are different is the definition of identifying an effect modifier, not controlling a confounder.
Confounding is a nuisance variable to be eliminated (resulting in one adjusted estimate), whereas effect modification is a biological reality to be described (resulting in separate estimates).

Key Concept

Methods for controlling confounding in observational studies (Restriction, Matching, Stratification, Multivariable Regression).
Question 4099Question →

A 68-year-old woman with type 2 diabetes mellitus, essential hypertension, and a history of a transient ischemic attack (TIA) 2 years ago visits her primary care physician. She is currently asymptomatic and recovering well. Her most recent hemoglobin A1c is 7.1%7.1\% on a regimen of metformin and glipizide. Her blood pressure is 128/78 mmHg128/78 \text{ mmHg} on lisinopril. Echocardiography performed last year showed normal left ventricular size and systolic function with an estimated ejection fraction of 60%60\%.

She brings in a pharmaceutical magazine advertisement for a new sodium-glucose cotransporter-2 (SGLT2) inhibitor, "CardioGlitin." The advertisement prominently features the claim: "Proven to reduce the risk of major cardiovascular events by 18%18\%!" The patient is very anxious about having a full stroke and asks if she should switch to this new medication specifically to lower her risk.

The physician reviews the pivotal randomized controlled trial referenced in the advertisement. The trial evaluated the drug against placebo in over 8,000 patients with type 2 diabetes and high cardiovascular risk over 4 years. The results for the primary composite endpoint (major adverse cardiovascular events) and its individual components are presented below:

OutcomeHazard Ratio (95%95\% CI)
Primary Composite Endpoint0.820.82 (0.73−0.920.73 - 0.92)
Cardiovascular Death0.980.98 (0.85−1.130.85 - 1.13)
Non-fatal Myocardial Infarction0.950.95 (0.81−1.110.81 - 1.11)
Non-fatal Stroke1.041.04 (0.87−1.240.87 - 1.24)
Hospitalization for Heart Failure0.610.61 (0.50−0.740.50 - 0.74)

Based on the provided trial data, which of the following is the most appropriate response to the patient's inquiry?

Show answer & explanation

Answer: The advertised overall benefit is primarily driven by a reduction in heart failure admissions, and the trial data does not show a statistically significant reduction in the risk of stroke.

Answer

The most appropriate response is that the advertised benefit is driven by a reduction in heart failure admissions, and there is no statistically significant reduction in the risk of stroke.
The correct answer accurately interprets the provided statistical data. While the advertisement truthfully claims an 18%18\% reduction in major cardiovascular events (the primary composite endpoint, HR 0.820.82), a closer look at the trial data reveals that this benefit is driven entirely by a reduction in hospitalizations for heart failure (HR 0.610.61, 95%95\% CI 0.50−0.740.50 - 0.74). The patient is specifically asking about stroke prevention. The hazard ratio for non-fatal stroke is 1.041.04 with a 95%95\% confidence interval of 0.87−1.240.87 - 1.24. Because this interval crosses the null value of 1.01.0, the trial failed to demonstrate a statistically significant benefit for stroke prevention. The physician must accurately translate these nuances to the patient rather than taking the composite marketing claim at face value.

Step-by-Step Solution

1
Identify the patient's specific clinical goal.
The patient wants to know if the medication will lower her risk of having a stroke.
Treatment decisions must align the available evidence with the patient's specific clinical needs and concerns.
2
Analyze the primary composite endpoint in the provided table.
The primary composite endpoint shows a statistically significant benefit with a Hazard Ratio of 0.820.82 (an 18%18\% relative risk reduction) because the 95%95\% confidence interval (0.73−0.920.73 - 0.92) does not cross 1.01.0.
This confirms the advertisement's claim is technically accurate based on the overall composite outcome.
3
Evaluate the individual components comprising the composite endpoint.
The only individual component that is statistically significant is 'Hospitalization for Heart Failure' (HR 0.610.61, 95%95\% CI 0.50−0.740.50 - 0.74). The components for CV Death, MI, and Stroke all have confidence intervals that cross 1.01.0.
Composite endpoints pool different events to increase statistical power, but a large effect size in one component can drive the entire result, masking null effects in others.
4
Correlate the findings with the patient's goal.
The Hazard Ratio for non-fatal stroke is 1.041.04 (95%95\% CI 0.87−1.240.87 - 1.24). Because the confidence interval crosses 1.01.0, the drug does not significantly reduce stroke risk.
The physician must educate the patient that the marketing claim, while true for the composite endpoint, does not apply to her specific clinical goal of stroke prevention.

Key Concept

Deconstructing composite endpoints and interpreting confidence intervals for individual components in medical literature.
Estimated Time:1m 30s
Question 4100Question →

A sleep medicine physician conducts a crossover study to evaluate the efficacy of a novel non-benzodiazepine hypnotic agent compared to placebo in patients with chronic insomnia. Twenty patients are enrolled. Each patient receives the placebo for one week, undergoes a one-week washout period, and then receives the active medication for one week. The primary outcome is the average sleep onset latency, measured in minutes via polysomnography at the end of each treatment period. A preliminary analysis of the data reveals that the differences in sleep onset latency between the two treatment periods are markedly skewed and do not adhere to a normal distribution. Which of the following statistical tests is most appropriate to determine if there is a significant difference in sleep onset latency between the two treatments?

Show answer & explanation

Answer: Wilcoxon signed-rank test

Answer

Wilcoxon signed-rank test
The correct test is the Wilcoxon signed-rank test. The scenario describes a crossover study evaluating two treatments within the exact same patients, which means the data are paired. The primary outcome, sleep onset latency in minutes, is a continuous variable. However, because the differences between the paired values are markedly skewed, parametric tests (which assume normality) are contraindicated. The Wilcoxon signed-rank test is the appropriate non-parametric statistical method for analyzing differences in paired, continuous variables that do not follow a normal distribution.

Step-by-Step Solution

1
Determine the study design and the relationship between the groups being compared.
The study uses a crossover design where each patient receives both treatments, meaning the data are paired or matched.
Test selection depends fundamentally on whether the groups are independent or paired.
2
Identify the dependent (outcome) variable's data type.
The outcome is sleep onset latency measured in minutes, which is a continuous variable.
Different test families are required for continuous, ordinal, or categorical outcome variables.
3
Assess the distribution of the data.
The differences in sleep onset latency between the two periods are markedly skewed, violating the assumption of normality.
Parametric tests require normal distributions; significant skewness dictates the use of a non-parametric alternative.
4
Select the appropriate statistical test based on the collected parameters.
The Wilcoxon signed-rank test is selected because it is the non-parametric equivalent of the paired t-test, designed for two paired groups with a skewed continuous outcome.
This test ranks the absolute differences between the paired observations rather than analyzing the raw means, safely accommodating non-normal data.

Key Concept

Selection of the Wilcoxon signed-rank test for paired, continuous data with a non-normal distribution.
PreviousPage 205 / 237Next
All practice questions — USMLE Step 3 | Examkin